PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy

Cancer Research

Volumn 75, Issue 10, 2015, Pages 1944-1948

  Hsieh, Chen Lin ^a   Botta, Ginevra ^a,b   Gao, Shuai ^a   Li, Tiantian ^a   Van Allen, Eliezer M ^a   Treacy, Daniel J ^a   Cai, Changmeng ^a   He, Housheng Hansen ^c,d   Sweeney, Christopher J ^a   Brown, Myles ^a   Balk, Steven P ^a   Nelson, Peter S ^e   Garraway, Levi A ^a,b   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZALUTAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KRUPPEL LIKE FACTOR; PHENYLTHIOHYDANTOIN; TRANSCRIPTOME; ZBTB16 PROTEIN, HUMAN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE SILENCING; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PLZF GENE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE, NUDE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930215434     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3602     Document Type: Article

References (16)

1. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 2014;14:187-98.
2. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 2014;40:426-33.
3. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 May 19. [Epub ahead of print].
4. Claessens F, Helsen C, Prekovic S, den Broeck TV, Spans L, Poppel HV, et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol 2014;11:712-6.
5. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013;31:1866-73.
6. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, et al. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003;23:9375-88.
7. Suliman BA, Xu D, Williams BR. The promyelocytic leukemia zinc finger protein: two decades of molecular oncology. Front Oncol 2012;2:74.
8. Jiang F, Wang Z. Identification and characterization of PLZF as a prostatic androgen-responsive gene. Prostate 2004;59:426-35.
9. Kikugawa T, Kinugasa Y, Shiraishi K, Nanba D, Nakashiro K, Tanji N, et al. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate 2006;66: 1092-9.
10. Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, et al. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A 2014;111:7319-24.
11. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
12. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014;33:2815-25.
13. Shi J, Vogt PK. Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer 2009;125:1558-65.
14. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A 2013;110:E4762-9.
15. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 2013;3:44-51.
16. De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, et al. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis 2014;35:2142-53.